2012 Keppra Family Epilepsy Scholarship Program

Award Amount
$5000 Deadline Date
May 27 Awards Available
30

Description

WHO: People with epilepsy and their family members or caregivers can apply for a scholarship through the Keppra® (levetiracetam) Family Epilepsy Scholarship ProgramTM, which provides financial resources to those who demonstrate academic and personal achievement.

WHAT: UCB, Inc. will award 30 one-time scholarships in 2012 as follows:
– Twenty $5,000 scholarships to people with epilepsy
– Ten $5,000 scholarships to family members or caregivers of people with epilepsy
WHERE: To download a copy of the scholarship application, go to www.KEPPRA.com.

To apply, you must certify that you are
– A legal and permanent resident of the United States
– A person with epilepsy or a family member/caregiver of a person with epilepsy
– Seeking an undergraduate or graduate degree
– A student who demonstrates academic achievement, possesses a strong record of participation in activities outside of school, and serves as a positive role model
– Graduating from high school in 2012 or have already graduated from high school
– Enrolled in or awaiting acceptance from a United States–based institution of higher education for fall semester 2012

WHEN: The completed application must be postmarked by May 25, 2012. Scholarship winners will be notified in August.

WHY: UCB, Inc. is a biopharmaceutical company committed to establishing itself as The Epilepsy Company™ through innovative research and development and by offering epilepsy-related programs that enrich the lives of people with epilepsy, caregivers, and healthcare providers. Through the scholarship program, UCB Inc. hopes to encourage those who are affected by epilepsy to continue their education despite the day-to-day challenges that epilepsy may pose.
– The Keppra® Family Epilepsy Scholarship ProgramTM was founded in 2005
– To date, a total of 45 scholarships have been awarded

For additional information about The Keppra® Family Epilepsy Scholarship ProgramTM, please contact:

Sarah B. Shpetner
Director, Account Services
Hudson Medical Communications
200 White Plains Road, 2nd Floor
Tarrytown, NY 10591
Phone: 914-332-1515, ext.164
Fax: 914-332-7171
E-mail: sshpetner@hudsonmc.com


IMPORTANT SAFETY INFORMATION

Keppra® is indicated as adjunctive therapy in the treatment of partial onset seizures in adults and children 4 years of age or older with epilepsy and myoclonic seizures in adults and adolescents 12 years of age and older with juvenile myoclonic epilepsy.

Keppra® is associated with the occurrence of central nervous system adverse events including somnolence and fatigue and behavioral abnormalities, as well as hematological abnormalities. In adults experiencing partial onset seizures, Keppra® is also associated with coordination difficulties. In pediatric patients 4-16 years of age experiencing partial onset seizures, the most common adverse events associated with Keppra® in combination with other AEDs were somnolence, accidental injury, hostility, nervousness and asthenia. In adults experiencing partial onset seizures, the most common adverse events associated with Keppra® in combination with other AEDs were somnolence, asthenia, infection and dizziness. In patients 12 years of age and older with juvenile myoclonic epilepsy, the most common adverse events associated with Keppra® in combination with other AEDs were somnolence, neck pain, and pharyngitis.

Click here for full Keppra® prescribing information.


Website Address

http://www.keppra.com